---
layout: default
title: "Case PPEGC-2025-0003"
---

# Case PPEGC-2025-0003

**Submitting Institute:** Asian institution (ASI-091), Japan  
**Publication Date:** February 17, 2025  
**DOI:** 10.ppegc/2025-0003

---

## Clinical Information

| | |
|---|---|
| **Cancer Type** | Metastatic colorectal adenocarcinoma |
| **Stage** | Stage IV |
| **Patient Age Range** | 60-65 years |
| **Sex** | Female |
| **Treatment** | FOLFIRI + Cetuximab |
| **Prior Lines** | Second-line (post-FOLFOX) |

---

## Genomic Profile

| Gene | Variant (HGVS) | VAF | Type |
|---|---|---|---|
| KRAS | NM_033360.4:c.34G>T (p.Gly12Cys) | 48% | Somatic |
| UGT1A1 | *28/*28 genotype | ‚Äî | Germline |
| DPYD | NM_000110.4:c.1905+1G>A (IVS14+1G>A) | 50% | Germline |

**Sequencing Method:** NGS panel + pharmacogenomic profiling

---

## Exceptional Phenotype

**Type:** Unusual toxicity

**Description:**  
Patient with metastatic colorectal cancer treated with FOLFIRI chemotherapy. Despite KRAS G12C mutation (typically contraindicating anti-EGFR therapy), cetuximab was added per clinical trial protocol. Patient developed severe, life-threatening toxicity (Grade 4 diarrhea, Grade 4 neutropenia) requiring ICU admission.

**Timeline:**
- Cycle 1, Day 1: FOLFIRI + cetuximab initiated
- Day 5: Onset of severe diarrhea (10+ stools/day)
- Day 7: Febrile neutropenia (ANC 100/ŒºL), hospitalized
- Day 10: ICU admission for septic shock
- Day 15: Recovery, treatment permanently discontinued

**Exceptional Features:**
1. Severity disproportionate to standard FOLFIRI toxicity profile
2. UGT1A1 *28/*28 homozygosity (known irinotecan risk factor)
3. Novel DPYD IVS14+1G>A variant detected retrospectively
4. Combination of two germline pharmacogenomic risk alleles

**Post-Event Pharmacogenomic Analysis:**
- UGT1A1 *28/*28: Associated with severe irinotecan toxicity
- DPYD IVS14+1G>A: Splicing variant, reduced DPD enzyme activity (5-FU metabolism)
- Combined genotype predicted severe toxicity risk

**Clinical Outcome:**  
Patient recovered fully. Switched to capecitabine monotherapy (no further toxicity). Stable disease maintained for 8 months.

---

## Key Insights

- Highlights importance of pre-treatment pharmacogenomic screening
- First report combining UGT1A1 *28/*28 + DPYD IVS14+1G>A in CRC patient
- Suggests additive toxicity risk with multiple pharmacogenomic variants
- Case contributed to institutional policy change: mandatory DPYD/UGT1A1 testing before FOLFIRI

---

## Interested in this case?

üìß **Request contact with the submitting clinician**  
[Contact PPEGC](mailto:curation@ppegc.org?subject=Contact%20Request%20-%20PPEGC-2025-0003)

üìù **Report a similar case**  
[Submit your case](https://redcap.link/ppegc-submit)

ü§ù **Propose a research collaboration**  
[Collaboration inquiry](mailto:research@ppegc.org?subject=Collaboration%20-%20PPEGC-2025-0003)

---

## Citation

**Recommended citation:**
```
Asian Contributor. (2025). Colorectal cancer with compound UGT1A1/DPYD variants 
causing severe FOLFIRI toxicity. Platform for Exceptional Genomic Cancer Cases 
(PPEGC). DOI: 10.ppegc/2025-0003
```

---

## Related Cases

- [PPEGC-2025-0006](#) ‚Äî HER2+ gastric cancer with trastuzumab cardiotoxicity
- [PPEGC-2025-0011](#) ‚Äî Pancreatic cancer with gemcitabine hypersensitivity

---

*Published: February 17, 2025*  
*Last updated: February 17, 2025*

[‚Üê Back to all cases](../cases.html) | [Home](../index.md)
